Austin, TX & Boston, MA – Our team is thrilled to announce that we’ve raised a major new round: a $15 million Series A.
The Series A funding will accelerate the development of both our flagship product, QbDVision, and our broader mission to shape the digital future of life science manufacturing. QbDVision is poised to accelerate the digital maturity of chemistry, manufacturing, and controls (CMC), as well as the drug development workstreams that depend on those specialized operations.
Led by Northpond Ventures, a leading science- and technology-driven venture capital firm, with follow-on investment from S3 Ventures, Wanxiang Healthcare Investments, and Hudson Park Capital, this round will fund further expansion of a broad commercial market that already includes a wide range of customers – enterprise pharma, up-and-coming biotechs, CDMOs, and more. Northpond’s commitment adds our team and product to a fast-growing portfolio of scientific, therapeutic, and digital innovations.
INVESTORS SEE AN OVERLOOKED OPPORTUNITY IN BIOPHARMA’S DIGITAL TRANSFORMATION
“QbDVision is part of an exciting new wave of digital transformation in the life sciences,” says Paxton Major, Senior Associate at Northpond Ventures, “but it also fills a critical gap in the solutions that this innovation cycle is delivering across the drug development process.”
“AI is transforming drug discovery,” Major notes, “Real-world evidence (RWE) is reshaping the clinical development enterprise. Commercial and medical affairs organizations are leveraging advanced analytic tools. We’re seeing a remarkable rate of digitization up and down the product life cycle – except in CMC. QbDVision closes this gap elegantly. It’s the first cloud-based workspace for product and process development, a solution that brings digital structure, efficiency and precision to CMC workflows in just a few clicks”.
"We’re seeing a remarkable rate of digitization up and down the product life cycle – except in CMC. QbDVision closes this gap elegantly. It’s the first cloud-based workspace for product and process development, a solution that brings digital structure, efficiency and precision to CMC workflows in just a few clicks."
Our seasoned QbDVision team has further reinforced their investors’ confidence.
“Since our initial Seed investment, we have been impressed by the strength of the product team behind QbDVision, and by the boldness of their vision,” says Eric Engineer, Partner at S3 Ventures. “They bring that special blend of domain experience and technical acumen — a combination that is sure to deliver technology that will transform how the pharmaceutical industry operates. We are thrilled to increase our investment with this round.”
"They bring that special blend of domain experience and technical acumen — a combination that is sure to deliver technology that will transform how the pharmaceutical industry operates."
A CRITICAL NEW TOOL FOR CMC TEAMS AND OPERATIONS
For pharma and biotech companies, QbDVision can bring much-needed transformation to a digitally underserved component of their operations.
While many pharma and biotech companies have been racing to adopt new tech, digital maturity has lagged for complex CMC activities that take place between newly AI-powered discovery processes and robotically enhanced commercial manufacturing. Many CMC workflows remain manual, siloed, and document-centric, leaving companies vulnerable to data integrity issues, internal knowledge gaps, fragmented process understanding, and costly regulatory setbacks.
These risks haven’t been lost on the US Food and Drug Administration (FDA). The agency recently funneled fresh investment to their Knowledge-Aided Assessment and Structured Application (KASA) program – an initiative focused on shifting the industry toward digitization and structured data frameworks.
"QbDVision breaks down information silos, centralizes dispersed knowledge, and connects it in ways that make it shareable, contextual, and insightful. In QbDVision, CMC data finally becomes the invaluable strategic asset it should be – not just for the team producing it, but for the whole organization."
QbDVision was purpose-built to help CMC teams make this shift – and with drug manufacturing in the pandemic’s global spotlight, the industry racing to the cloud, and a new wave of complex therapies on the horizon, demand for this software is growing rapidly. Multiple top-tier pharma and biotech organizations have already deployed QbDVision across their development cycles, giving their CMC teams a structured approach to consolidating knowledge, integrating workflows, and curating data in ways that significantly enhance operational efficiency.
“Our software finally makes CMC data FAIR: findable, accessible, interoperable, and reusable,” says Yash Sabharwal, CEO. “QbDVision breaks down information silos, centralizes dispersed knowledge, and connects it in ways that make it shareable, contextual, and insightful. In QbDVision, CMC data finally becomes the invaluable strategic asset it should be – not just for the team producing it, but for the whole organization.”
A NEW STEP IN THE EVOLVING DIGITAL FUTURE OF R&D
For our team, bringing this kind of operational sophistication to CMC teams is the first step in a longer-term vision for the digital transformation of drug development and manufacturing.
By leveraging QbDVision, today’s process developers can already generate insights and drive efficiencies that help accelerate the development of new drug therapies. But our team also believes that many other groups, functions, and partners across the manufacturing value chain could also benefit from managing their workflows and data resources in the same structured framework.
"We’re helping R&D teams break free from today’s inefficient, PDF-driven approach to process development. With QbDVision, CMC teams can work smarter, work more efficiently, and start creating the structured data they need to put their processes on a path to automation."
“Life science companies and their manufacturing partners are facing a whole new level of complexity right now,” notes our CTO Ryan Shillington. “Value-based care models are driving a surge in demand for patient-friendly combination products, which bring together all the chemical complexities of manufacturing a drug therapy and the engineering complexity of manufacturing a device.”
As Ryan notes, “Modern digital process infrastructure will be vital to the increasing number of teams that will be tasked with shepherding these complex products to the market. We want our software portfolio to lay the foundation they need.”
For us, the next phase in the development of QbDVision will be focused on driving operational excellence across the drug development cycle. As Yash adds, “We’re helping R&D teams break free from today’s inefficient, PDF-driven approach to process development” – a status quo where far too many late-cycle steps get bogged down in documents at the regulatory finish line.
“With QbDVision, CMC teams can work smarter, work more efficiently, and start creating the structured data they need to put their processes on a path to automation.”
And for our team, that means not only streamlining CMC operations, but also accelerating new products from scientific innovation to life-changing therapy.
JOIN OUR TEAM OF DREAMERS AND VISIONARIES
As we continue on our journey, we’ll be seeking more dreamers, visionaries, makers, and doers to join our team. If you know anyone who would fit right in, or if you’re looking, we’d love to hear from you!
